

# Anxiety Disorders: Market Research Report

<https://marketpublishers.com/r/AD26263E219EN.html>

Date: March 2012

Pages: 615

Price: US\$ 4,800.00 (Single User License)

ID: AD26263E219EN

## Abstracts

This report analyzes the worldwide markets for Anxiety Disorders in US\$ Million.

The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 63 companies including many key and niche players such as AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-la Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan, Inc., Neurocrine Biosciences, Inc., Pfizer, Inc., Ratiopharm, Sanofi, UCB SA, Valeant Pharmaceuticals International, and Watson Laboratories, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based upon search engine sources in the public domain.

## Contents

### I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study

### II. EXECUTIVE SUMMARY

#### 1. INDUSTRY OVERVIEW

Anxiety Disorders: A Prelude  
Future Outlook – Market Challenged by Generics and Efficacy Issues  
A Snapshot of the Global Market Opportunity  
Prevalence of Specific Anxiety Disorders  
Generalized Anxiety Disorder (GAD)  
Obsessive-Compulsive Disorder (OCD)  
Specific Phobias  
Social Phobias  
Panic Disorder  
Post Traumatic Stress Disorder (PTSD)  
Social Anxiety Disorder (SAD)  
Anxiety Disorders Can Strike At Any Age  
Shyness: A Form of Anxiety Disorder among Kids and Teenagers

**Table 1.** Average Age of Onset for Select Anxiety Disorders (includes corresponding Graph/Chart)

Women - The Most Affected Lot with Anxiety

**Table 2.** Female to Male Ratio for Incidence of Anxiety Disorders by Type of Disorder (includes corresponding Graph/Chart)

Patent Expiries – A Major Impediment to Market Growth

Patent Expiries of Select Leading Drugs Indicated for Anxiety Disorders  
Leading Drugs and Indications for Anxiety Disorders

## 2.PHARMACOLOGICAL TREATMENT FOR ANXIETY DISORDERS

Pharmacological Treatment

Available Treatment for Anxiety Disorders – In a Nutshell

Antidepressants for Anxiety Disorders

Selective Serotonin Reuptake Inhibitors (SSRIs)

Zoloft (Sertraline)

Paxil (Paroxetine)

Prozac (Fluoxetine)

Cipralex/Lexapro (Escitalopram)

Competitive Scenario - Cymbalta Emerges as a Market Leader in Anti-Depressants Market

**Table 3.** Select Leading Anti-Depressants indicated for Anxiety Disorders (2007-2009): Annual Revenues for Cymbalta, Lexapro, Paxil & Wellbutrin, Effexor, Zoloft, and Remeron in US\$ Million (includes corresponding Graph/Chart)

Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)

Cymbalta (Duloxetine)

Effexor (Venlafaxine)

Monoamine Oxidase Inhibitors (MAOIs)

Tricyclic and Tetracyclic Antidepressants (TCAs)

Other Antidepressants

Sedatives

Benzodiazepines (BZDs)

Other Medications

Obsessive Compulsive Disorder (OCD) Treatment

**Table 4.** Dosing of Select Serotonin Reuptake Inhibitors in OCD Treatment

Generalized Anxiety Disorder (GAD) Treatment

Drugs Indicated for the Treatment of Generalized Anxiety Disorder (GAD)

Novel Therapies for GAD on the Anvil

Novel Compounds Under Investigation for Generalized Anxiety Disorder (GAD)

### **3.DRUG PIPELINE ANALYSIS**

Select Anti-Anxiety Pipeline Drugs in Phase III Development Stage and Filed for Approval

Select Anti-Anxiety Pipeline Drugs in Phase II Development Stage

Select Anti-Anxiety Pipeline Drugs in Phase I Development Stage

### **4.NON-PHARMACOLOGICAL TREATMENT**

Psychological Treatment

Cognitive Behavioral Therapy

Relaxation Techniques

Biofeedback

Hypnotherapy

Meditation

Natural Remedies for Treating Anxiety

Acupuncture

Other Treatment Options

Support Program

Changes in Lifestyle

### **5.ANXIETY DISORDERS – THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS**

What is Anxiety Disorder?

Types of Anxiety Disorders

A Review of Anxiety Disorders

Generalized Anxiety Disorder (GAD)

Panic Disorder

Phobias

Agoraphobia

Social Phobia

Obsessive-Compulsive Disorder (OCD)

Symptoms, Obsessions and Compulsions of Obsessive-Compulsive Disorder

Particular Phobic Anxiety Disorder (PPAD)

Post-Traumatic Stress Disorder (PTSD)

Separation Anxiety Disorder (SAD)

Anxiety Disorders in Children

Anxiety Disorders in Teens  
Causes and Factors for Anxiety Disorder  
Symptoms  
Diagnosis for Anxiety Disorders

## **6.PRODUCT APPROVALS AND LAUNCHES**

Sun Pharma Receives FDA Approval to Commercialize Generic Cymbalta  
Impax Receives Tentative FDA Approval for Generic Version of Cymbalta  
Actavis Receives FDA Approval for Alprazolam  
Sun Pharma Receives FDA Approval to Generic Version of Alprazolam  
Bafna Pharmaceuticals Receives Approval for Anxiety Drug in UK  
Coenzyme-A Technologies Introduces MODULATOR MATRIX I  
Sun Pharma to Launch Generic Version of Venlafaxine  
Eli Lilly Receives FDA Approval for Cymbalta for Treating GAD  
Aurobindo Pharma Receives Tentative US FDA Approval for Escitalopram  
Boehringer Ingelheim and Eli Lilly Obtain Approval for Cymbalta in Canada  
Medtronic's Reclaim Deep Brain Stimulation Therapy Receives CE-Mark Approval  
Otsuka Pharmaceutical and BMS Obtain FDA Approval for sNDA  
Servier Obtains EMEA Approval for Valdoxan in Treating Major Depressive Episodes  
Boehringer Ingelheim and Eli Lilly Receive EU Approval for Cymbalta in GAD  
AstraZeneca Files for Approval of Seroquel XR for GAD in Europe  
Glenmark Pharmaceuticals Launches Hydroxyzine Hydrochloride Tablets  
Jazz Pharma Launches Once-A-Day LUVOX® CR Extended-Release Capsules

## **7.RECENT INDUSTRY ACTIVITY**

Euthymics Acquires DOV Pharma  
Abbott Acquires Solvay Pharmaceuticals  
Pfizer Withdraws sNDA for Lyrica in Treating GAD  
Eli Lilly Drags Sun Pharma to Court for Alleged Infringement of Cymbalta Patent  
Pfizer Discontinues Late Stage Development of GAD Drug Candidate  
Pacgen Biopharmaceuticals Acquires Xphase Pharmaceuticals  
GSK Inks Agreement for Divesting Wellbutrin XL® Rights to Biovail International  
Ligand Pharmaceuticals Acquires Neurogen  
FDA Seeks Additional Information for Seroquel XR sNDA in GAD Treatment  
AstraZeneca's Seroquel XR™ Shows Improvement in GAD Symptoms  
Synosia Therapeutics Begins Phase II Efficacy Trial for Rufinamide  
Ambien CR® Improves Chronic Insomnia in Patients with Co-morbid GAD

AstraZeneca Files sNDA for Seroquel XR for Treating GAD  
Bionomics Concludes GMP Synthesis of BNC210  
OJSC Pharmstandard to Take Over Afobazol® Trademark

## 8.FOCUS ON SELECT GLOBAL PLAYERS

AstraZeneca Plc. (UK)  
Boehringer Ingelheim GmbH (Germany)  
Bristol-Myers Squibb Company (US)  
Eli Lilly and Company (US)  
F. Hoffmann-La Roche Ltd. (Switzerland)  
Forest Laboratories, Inc. (US)  
GlaxoSmithKline Plc. (UK)  
H. Lundbeck A/S (Denmark)  
Mylan, Inc. (US)  
Neurocrine Biosciences, Inc. (US)  
Pfizer, Inc. (US)  
Ratiopharm (Germany)  
Sanofi (France)  
UCB SA (Belgium)  
Valeant Pharmaceuticals International (US)  
Watson Laboratories, Inc. (US)

## 9.GLOBAL MARKET PERSPECTIVE

**Table 5.** World Recent Past, Current and Future Analysis for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 6.** World Historic Review for Anxiety Disorders by Geographic Region – US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 7.** World 15-Year Perspective for Anxiety Disorders by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. Market Analysis

Anxiety Disorders – A Major Health Burden

Prevalence of Anxiety Disorders

**Table 8.** US Prevalence of Anxiety Disorders by Type (includes corresponding Graph/Chart)

Product Approvals and Launches

Strategic Corporate Developments

Select Players

Bristol-Myers Squibb Company

Eli Lilly and Company

Forest Laboratories, Inc.

Mylan, Inc.

Neurocrine Biosciences, Inc.

Pfizer, Inc.

Valeant Pharmaceuticals International

Watson Laboratories, Inc.

B. Market Analytics

**Table 9.** The US Recent Past, Current & Future Analysis for Anxiety Disorders Market With Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 10.** The US Historic Review for Anxiety Disorders Market With Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

#### 2. EUROPE

##### A. Market Analysis

Product Approval

B. Market Analytics

**Table 11.** European Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 12.** European Historic Review for Anxiety Disorders Market by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

**Table 13.** European 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

## **2A.FRANCE**

- A. Market Analysis
  - Clinical Trials/Product Approvals
  - Select Player
- B. Market Analytics

**Table 14.** French Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 15.** French Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **2B.GERMANY**

- A. Market Analysis
  - Product Approval
  - Select Players
- B. Market Analytics



**Table 16.** German Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 17.** German Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **2C.ITALY**

A. Market Analysis

Select Player

Polifarma SpA

B. Market Analytics

**Table 18.** Italian Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 19.** Italian Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **2D.THE UNITED KINGDOM**

A. Market Analysis

An Overview of the Market Opportunity

**Table 20.** Prevalence of Depression and Anxiety Disorders in the UK (2006): Percentage of Adult Population (16-75 Years) Affection by Condition (includes corresponding Graph/Chart)

Product Approvals/Clinical Trials

Select Players

B. Market Analytics

**Table 21.** The UK Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 22.** The UK Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **2E.SPAIN**

Market Analytics

**Table 23.** Spanish Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 24.** Spanish Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **2F.REST OF EUROPE**

A. Market Analysis

Strategic Corporate Development

Select Players

B. Market Analytics

**Table 25.** Rest of European Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 26.** Rest of European Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## **3.ASIA-PACIFIC**

## A. Market Analysis

Anxiety and Depression – A Major Debilitating Condition in Australia

**Table 27.** 12-Month Prevalence of Anxiety Disorders in Australia by Age Group (2006)  
(includes corresponding Graph/Chart)

Strategic Corporate Development

Select Player

## B. Market Analytics

**Table 28.** Asia-Pacific Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 29.** Asia-Pacific Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## 4.REST OF WORLD

### A. Market Analysis

Product Approval

Select Player

Ranbaxy Egypt Ltd. (Egypt)

### B. Market Analytics

**Table 30.** Rest of World Recent Past, Current & Future Analysis for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

**Table 31.** Rest of World Historic Review for Anxiety Disorders Market with Annual Sales Figures in US\$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

## IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 85)

Region/Country

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Rest of Europe

Asia-Pacific (Excluding Japan)

Africa

Middle East

## I would like to order

Product name: Anxiety Disorders: Market Research Report

Product link: <https://marketpublishers.com/r/AD26263E219EN.html>

Price: US\$ 4,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AD26263E219EN.html>